In the last 20 years, India has experienced an epidemic explosion of diabetes with a 2.5 fold increase in the number of diabetics since 1990 (1). Although a good number of new classes of drugs are available to physicians for diabetes management, sulfonylureas (SUs) remained a frequently prescribed anti-diabetic agent due to its effectiveness, good tolerability, once-daily oral dosing and inexpensiveness (2,3). In addition to this, the last two decades have witnessed a lower risk of hypoglycemia and weight gain with modern SU Glimepiride (4). Therefore the question arises, "Should 20 years of experience be challenged?" Sanofi and Docplexus have organized an interactive webinar on 28th May at 2:30 pm for the same question.
In this webinar session, Dr. Shashank R. Joshi will talk about 20 Years Of Experience With Glimepiride . …
